Vanessa Hayes | |
---|---|
Born | Cape Town, South Africa |
Citizenship | Australia |
Awards | Fellow of the Australian Academy of Health and Medical Sciences (2024) |
Scientific career | |
Fields | Cancer genomics, comparative human genomics |
Vanessa Hayes is a geneticist conducting research into cancer genomics and comparative human genomics. She leads a research group at the Garvan Institute of Medical Research in Sydney Australia [1] and holds the Petre Chair of Prostate Cancer Research at the University of Sydney. [2]
Hayes was born in Cape Town, South Africa. She undertook BSc and Masters education at Stellenbosch University [3] In 1999 she completed PhD studies in cancer genetics at the University of Groningen, Netherlands. [4]
Hayes' first research position was at Stellenbosch University, investigating genetic susceptibility to HIV/AIDS. [4] [5] Her work identified the lack of knowledge about African gene variants that hindered pharmacogenomics research, including into the efficacy of HIV treatments. [6]
In 2003 Hayes moved to Sydney, Australia, to lead research into cancer genetics at the Garvan Institute of Medical Research. She subsequently joined the Children's Cancer Institute of Australia (CCIA) [4]
In 2009 Hayes was awarded a Fulbright professional scholarship to develop her expertise in genome analysis at Penn State University, with the intention of establishing a cancer genome research program focusing on prostate cancer, at the newly established UNSW Lowy Cancer Research Centre. [7]
While at the CCIA, Hayes worked on the South African Genome Project with researchers from the University of New South Wales and Penn State University in the US to compile the genome sequences of southern Africans, including Archbishop Desmond Tutu. [8] Until this research, most human genome sequences had been derived from people of European origin. Hayes and her collaborators revealed in 2010 that the genetic diversity among people in southern Africa is greater than among other populations worldwide. [9] [10]
In 2010 Hayes joined the J. Craig Venter Institute in San Diego, California, USA, where she continued her research into human genetic diversity. [4] That year she began leading a study sequencing DNA from a skeleton of an African hunter gatherer from around 315 BC found in St Helena Bay in South Africa. The DNA identified the skeleton as being from a man who was part of a previously unknown branch of the human family tree that diverged from the common lineage shared by all humans alive today. The study highlighted the significance of southern African archaeological remains in defining human origins and was published in the journal Genome Biology and Evolution in 2014. [11] [12] [13]
In 2011 Hayes was part of a research team that released details of Tasmanian devil population genetics, part of the research efforts towards understanding the devil facial tumour disease [14] [15]
Hayes's research also includes the study of prostate cancer genetics. One aspect has been investigating the genetic causes of aggressive prostate cancer that is seen in men of African ancestry [6]
Since January 2014, Hayes has held the Petre Chair of Prostate Cancer Research at the University of Sydney. [2] [16]
On Tuesday 23 February 2016 ABC broadcast an episode of Catalyst entitled 'Out of Africa' which explored Hayes's comparative genomics work in southern Africa. [17]
On Tuesday 23 October 2017, Hayes appeared on SBS Insight's “DNA Surprises” episode which dealt with the complex issues around ancestry testing through online companies, and particularly the unexpected information ancestry testing can uncover. [18]
John Shine is an Australian biochemist and molecular biologist. Shine and Lynn Dalgarno discovered a nucleotide sequence, called the Shine–Dalgarno sequence, necessary for the initiation of protein synthesis. He directed the Garvan Institute of Medical Research in Sydney from 1990 to 2011. From 2018 to 2022, Shine was President of the Australian Academy of Science.
The National Human Genome Research Institute (NHGRI) is an institute of the National Institutes of Health, located in Bethesda, Maryland.
Human genetic variation is the genetic differences in and among populations. There may be multiple variants of any given gene in the human population (alleles), a situation called polymorphism.
The Human Genome Project (HGP) was an international scientific research project with the goal of determining the base pairs that make up human DNA, and of identifying, mapping and sequencing all of the genes of the human genome from both a physical and a functional standpoint. It started in 1990 and was completed in 2003. It remains the world's largest collaborative biological project. Planning for the project began in 1984 by the US government, and it officially launched in 1990. It was declared complete on April 14, 2003, and included about 92% of the genome. Level "complete genome" was achieved in May 2021, with only 0.3% of the bases covered by potential issues. The final gapless assembly was finished in January 2022.
In molecular biology, SNP array is a type of DNA microarray which is used to detect polymorphisms within a population. A single nucleotide polymorphism (SNP), a variation at a single site in DNA, is the most frequent type of variation in the genome. Around 335 million SNPs have been identified in the human genome, 15 million of which are present at frequencies of 1% or higher across different populations worldwide.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.
The Garvan Institute of Medical Research is an Australian biomedical research institute located in Darlinghurst, Sydney, New South Wales. Founded in 1963 by the Sisters of Charity as a research department of St Vincent's Hospital, it is now one of Australia's largest medical research institutions, with approximately 750 scientists, students and support staff.
Rick Antonius Kittles is an American biologist specializing in human genetics and a Senior Vice President for Research at the Morehouse School of Medicine. He is of African-American ancestry, and achieved renown in the 1990s for his pioneering work in tracing the ancestry of African Americans via DNA testing.
Personal genomics or consumer genetics is the branch of genomics concerned with the sequencing, analysis and interpretation of the genome of an individual. The genotyping stage employs different techniques, including single-nucleotide polymorphism (SNP) analysis chips, or partial or full genome sequencing. Once the genotypes are known, the individual's variations can be compared with the published literature to determine likelihood of trait expression, ancestry inference and disease risk.
Whole genome sequencing (WGS) is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.
Christopher Carl Goodnow is an immunology researcher and the current executive director of the Garvan Institute of Medical Research. He holds the Bill and Patricia Ritchie Foundation Chair and is a Conjoint Professor in the faculty of medicine at UNSW Sydney. He holds dual Australian and US citizenship.
John Stanley Mattick is an Australian molecular biologist known for his efforts to assign function to non-coding DNA. Mattick was the executive director of the Garvan Institute of Medical Research from 2012 to 2018. He joined Genomics England in May 2018 as chief executive officer. In October 2019, he joined the University of New South Wales in Sydney.
The Cancer Genome Anatomy Project (CGAP), created by the National Cancer Institute (NCI) in 1997 and introduced by Al Gore, is an online database on normal, pre-cancerous and cancerous genomes. It also provides tools for viewing and analysis of the data, allowing for identification of genes involved in various aspects of tumor progression. The goal of CGAP is to characterize cancer at a molecular level by providing a platform with readily accessible updated data and a set of tools such that researchers can easily relate their findings to existing knowledge. There is also a focus on development of software tools that improve the usage of large and complex datasets. The project is directed by Daniela S. Gerhard, and includes sub-projects or initiatives, with notable ones including the Cancer Chromosome Aberration Project (CCAP) and the Genetic Annotation Initiative (GAI). CGAP contributes to many databases and organisations such as the NCBI contribute to CGAP's databases.
Nilanjan Chatterjee is a Bloomberg Distinguished Professor of Biostatistics and Genetic Epidemiology at Johns Hopkins University, with appointments in the Department of Biostatistics in the Bloomberg School of Public Health and in the Department of Oncology in the Sidney Kimmel Comprehensive Cancer Center in the Johns Hopkins School of Medicine. He was formerly the chief of the Biostatistics Branch of the National Cancer Institute's Division of Cancer Epidemiology and Genetics.
Katherine Belov is an Australian geneticist, professor of comparative genomics in the School of Life and Environmental Sciences and Pro Vice Chancellor of Global Engagement at the University of Sydney. She is head of the Australasian Wildlife Genomics Group and research expert in the area of comparative genomics and immunogenetics, including Tasmanian devils and koalas, two iconic Australian species that are threatened by disease processes. Throughout her career, she has disproved the idea that marsupial immune system is primitive, characterized the South American gray short-tailed opossum's immune genes, participated in the Platypus Genome Project, led research identifying the properties of platypus venom, and identified the cause of the spread of the Tasmanian devil's contagious cancer.
Clinicogenomics, also referred to as clinical genomics, is the study of clinical outcomes with genomic data. Genomic factors have a causal effect on clinical data. Clinicogenomics uses the entire genome of a patient in order to diagnose diseases or adjust medications exclusively for that patient. Whole genome testing can detect more mutations and structural anomalies than targeted gene testing. Furthermore, targeted gene testing can only test for the diseases for which the doctor screens, whereas testing the whole genome screens for all diseases with known markers at once.
Naomi Ruth Wray is an Australian statistical geneticist at the University of Queensland, where she is a Professorial Research Fellow at the Institute for Molecular Bioscience and an Affiliate Professor in the Queensland Brain Institute. She is also a National Health and Medical Research Council (NHMRC) Principal Research Fellow and, along with Peter Visscher and Jian Yang, is one of the three executive team members of the NHMRC-funded Program in Complex Trait Genomics. She is also the Michael Days Chair of Psychiatric Genetics at Oxford University. Naomi pioneered the use of polygenic scores in human genetics, and has made significant contributions to both the development of methods and their clinical use.
Susan J. Clark is an Australian biomedical researcher in epigenetics of development and cancer. She was elected a Fellow of the Australian Academy of Science in 2015, and is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow and Research Director and Head of Genomics and Epigenetics Division at the Garvan Institute of Medical Research. Clark developed the first method for bisulphite sequencing for DNA methylation analysis and used it to establish that the methylation machinery of mammalian cells is capable of both maintenance and de novo methylation at CpNpG sites and showed is inheritable. Clark's research has advanced understanding of the role of DNA methylation, non-coding RNA and microRNA in embryogenesis, reprogramming, stem cell development and cancer, and has led to the identification of epigenomic biomarkers in cancer. Clark is a founding member of the International Human Epigenome Consortium (IHEC) and President of the Australian Epigenetics Alliance (AEpiA).
Grant Robert Sutherland is a retired Australian human geneticist and cytogeneticist. He was the Director, Department of Cytogenetics and Molecular Genetics, Adelaide Women's and Children's Hospital for 27 years (1975-2002), then became the Foundation Research Fellow there until 2007. He is an Emeritus Professor in the Departments of Paediatrics and Genetics at the University of Adelaide.